Market Research Logo
Region: Europe
Category: Country Overviews

Europe Country Overviews

(129 reports matching your criteria)
  • Sweden Pharmaceuticals and Healthcare Report Q1 2016

    ...per capita spending, multinationalpharmaceutical companies will continue to be provided with steady revenue-earning opportunities. Suchdemographic trends will remain the primary driver of growth behind the prescription drug markets thoughwe highlight that the government is likely ... Read More

  • Netherlands Pharmaceuticals and Healthcare Report Q4 2015

    ...will provide a small boost to pharmaceutical sales in the near term. We forecast thepharmaceutical market will return to growth in 2016, the first time since 2011. Over the long term,medicine demand will be driven ... Read More

  • Lithuania Pharmaceuticals and Healthcare Report Q3 2015

    ...will support growth in spending on consumer healthcare products,namely OTC medicines. Headline Expenditure Projections Pharmaceuticals: EUR601mn (USD806mn) in 2014 to EUR618mn(USD680mn) in 2015; +2.7% inlocal currency terms and -15.7% in US dollar terms. Forecast revised ... Read More

  • Norway Pharmaceuticals and Healthcare Report Q3 2015

    ...manufacturers in the foreseeable future. Despite a comparativelysmaller market size, Norway's pharmaceutical sector, as distinct from several contracting drug markets inthe region, is expected to continue on its long-standing positive growth trajectory, creating opportunitiesfor drugmakers. ... Read More

  • Finland Pharmaceuticals and Healthcare Report Q3 2015

    ...high-value drugs in the medium-term. However,rising healthcare costs will place a heavy burden on government finances, requiring patented drug makersto prove the cost-effectiveness of their medicines over less expensive generic drugs. Headline Expenditure Projections Pharmaceuticals: ... Read More

  • Romania Pharmaceutical Report - Q1, 2015

    ...pace in Q1/2014 in RON and EUR terms, after having risen by 11.8% y/y in the previous quarter (up by 9.7% y/y in EUR terms). Sales of OTC drugs surged by 27.7% y/y to RON0.6bn, ... Read More

  • Latvia Pharmaceuticals and Healthcare Report Q2 2015

    ...size. Meanwhile,tensions between Ukraine and Russia may provide challenges for local manufacturers that had soughtexports to Russia and the Commonwealth of Independent States (CIS) region as a remedy for lacklustredomestic demand in recent years. Headline ... Read More

  • Belarus Pharmaceuticals and Healthcare Report Q2 2015

    ...two years. Furthermore, increased scrutiny by President Lukashenko over pharmaceutical imports indicates that Belarus may follow neighbouring Russia in instituting measures that favour the domestic industry and restrict the market for pharmaceutical imports. Headline Expenditure ... Read More

  • Estonia Pharmaceuticals and Healthcare Report Q2 2015

    ...jointly procure pharmaceuticals for their collective needs. Despite the small size of Estonia's pharmaceuticals industry, there is the potential for manufacturers to use the country as a low-cost export base, rather than focusing on the ... Read More

  • United Kingdom Pharmaceuticals and Healthcare Report Q2 2015

    ...is a key international player, and will continue to be for the foreseeable future. However, the climate of cost containment, coupled with patent expirations, will lower the overall value of the UK's drug market. Headline ... Read More

  • Ukraine Pharmaceuticals and Healthcare Report Q2 2015

    ...Eastern Ukraine and the severeerosion of consumer purchasing power resulting from a significant depreciation in the hryvnia. Withconsumer-spending the driving force behind pharmaceutical sales, the political and economic situation inUkraine will need to stabilise before ... Read More

  • Romania Pharmaceutical Report - Q4, 2014

    ...double-digit annual pace in Q4/2014 in RON terms. Sales of prescription based medicines (partly or fully subsidized) advanced by 9.6% y/y to RON2.4bn (€530mn), while OTC drug sales surged by 19.5% y/y over the quarter. ... Read More

  • France Pharmaceuticals and Healthcare Report Q2 2015

    ...capita spending levels on medicines. However, several cost-containment measures will continue to exert downward pressure on market growthover a multi-year horizon. On the upside, current macroeconomic trends, including low oil and food prices,should be net ... Read More

  • Romania Pharmaceuticals and Healthcare Report Q2 2015

    ...drive pharmaceuticalconsumption, but local regulatory factors such as revenue taxes will continue to present obstacles togrowth. Over the longer term, we expect the underfunding of the healthcare system to be addressed andgiven the country's ageing ... Read More

  • Bulgaria Pharmaceuticals and Healthcare Report Q2 2015

    ...healthcare financing, we holda more positive view for the long term development of the pharmaceutical & healthcare sector. Headline Expenditure Projections Pharmaceuticals: BGN2.50bn (USD1.71bn) in 2014 to BGN2.41bn (USD1.54bn) in 2015; -3.7% inlocal currency terms ... Read More

  • Germany Pharmaceuticals and Healthcare Report Q2 2015

    ...patented medicines. In spiteof this, additional restrictions on reimbursement, tempered by government's desire to preserve an industryintegral to Germany's positive balance of trade and international prestige, will nonetheless constrainrevenues and intensify already fierce competition amongst ... Read More

  • Czech Republic Pharmaceuticals and Healthcare Report Q2 2015

    ...decline. Indeed, thesechanges will help to provide for the growing demand for innovative drugs among the country's ageingpopulation. The healthcare spending of the Czech population remains superior to that of the less-developedmarkets of Eastern and ... Read More

  • Pharmaceuticals in France: ISIC 2423

    ...at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing ... Read More

  • Denmark Pharmaceuticals and Healthcare Report Q1 2015

    ...first time since 2009. Wemaintain our view that Denmark is an attractive market for drugmakers to operate in due to the country'shigh per-capita drug expenditure, transparent operating environment and strong regulatory climate.However, as the country's ... Read More

  • Romania Pharmaceutical Report - Q3, 2014

    ...as shown by official statistics. Imports dropped by 1.1% y/y to €1.5bn in January-July, after having increased by 7.8% y/y to € 2.7bn in full year 2013. Exports also declined by 10.5% y/y over the ... Read More

  • Poland Pharmaceuticals Report - 2014

    ...yet visibly, albeit slowly, recovering after the decline in 2012, when the entire pharma sector was affected by the price cut for reimbursed drugs, as part of the Reimbursed Act enforced and amended during the ... Read More

  • Pharmaceuticals and Healthcare Report - Greece Q4 2104

    ...The generic drug sector and private healthcare industrymay present some growth opportunities in the country. Headline Expenditure Projections Pharmaceuticals: EUR5.64bn (USD7.45bn) in 2013 to EUR5.28bn (USD7.07bn) in 2014; -6.5% inlocal currency terms and -5.1% in ... Read More

  • Pharmaceuticals and Healthcare Report - Czech Republic Q4 2014

    ...larger multinationals with competitive pressures expected tocontinue to favour those with scale. While we expect the Czech market to stabilise in 2014, we note thatdepreciatory pressure on the Czech koruna could see incomes decline for ... Read More

  • Pharmaceuticals and Healthcare Report - Denmark Q4 2014

    ...driven by its expanding aging population. However, this willsee the government continue to target the healthcare sector with cost-containment measures. Despite this,we believe Denmark will remain an attractive market for drugmakers to operate in due ... Read More

  • Pharmaceuticals and Healthcare Report - Finland Q4 2104

    ...we believe this will result in stronger downward price pressures onmedicines that treat long-term chronic diseases, with companies increasingly being required to prove thecost-effectiveness of innovative medicines in order to gain reimbursement. Headline Expenditure Projections ... Read More

1 2 4 6